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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects elderly
persons, evolving with age to reach severe cognitive impairment. Amyloid deposits and
neurofibrillary tangles constitute the main pathological hallmarks of AD. Amyloid deposits
are initiated by the excessive production and accumulation of beta-amyloid (Aβ) peptides
in the brain. The dysfunction of the Neurovascular Unit (NVU) has been proposed to be
causative in AD development, due to an impaired clearance of Aβ from the brain. Cells
forming the NVU express several Adenosine Triphosphate ATP-Binding Cassette (ABC)
transporters, among which ABCB1 and ABCA1 play an important role in Aβ processing.
The drug transporter ABCB1 directly transports Aβ from the brain into the blood circulation,
whereas the cholesterol transporter ABCA1 neutralizes Aβ aggregation capacity in an
Apolipoprotein E (ApoE)-dependent manner, facilitating Aβ subsequent elimination from
the brain. In the present minireview, we will summarize the contribution of ABCB1, and
ABCA1 at the NVU in Aβ clearance. Moreover, we will outline and discuss the possible
collaboration of ABCB1, and ABCA1 at the NVU in mediating an efficient clearance of Aβ
from the brain.
Keywords: Alzheimer’s disease, blood-brain barrier, neurovascular unit, ABCB1, ABCA1, apolipoprotein E,
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order that affects elderly persons. The pathogenesis of AD begins
with mild memory deficits and evolves to reach total cognitive
impairment and loss of executive functions (de Souza et al., 2009).
It is now widely accepted that amyloid deposits and neurofibril-
lary tangles formation constitutes the core pathological hallmarks
of AD (Selkoe, 2002). The sequential proteolytic cleavage of the
Amyloid Precursor Protein (APP) produces beta-amyloid (Aβ)
peptides, namely Aβ1−40 and Aβ1−42 (Hardy and Selkoe, 2002),
which oligomerize to form small oligomers of 2–12 peptides (i.e.,
Aβ oligomers), and aggregate leading to Aβ plaques generation
(Haass and Selkoe, 2007). Although the correlation between Aβ
parenchymal deposition and cognitive decline still remains con-
troversial, the detrimental role of soluble Aβ oligomers in the
brain of AD patients (Lue et al., 1999) and in mouse models of
AD (Cheng et al., 2007) has been demonstrated.
In more than 95% of AD cases, several environmental and
genetic factors that influence Aβ processing have been reported to
contribute in AD development (i.e., sporadic AD), among which
Aβ clearance and elimination from the brain play a central role
(Hardy and Selkoe, 2002). The remaining AD cases are caused
by an excessive Aβ production in the brain due to mutations in
either APP gene or the enzymes involved in its proteolytic cleav-
age (i.e., familial AD) (Levy-Lahad et al., 1995; Sherrington et al.,
1995).
The levels of soluble Aβ oligomers in the brain play a cru-
cial role in AD development, because their accumulation in brain
parenchyma causes neuronal dysfunction that have been shown to
take place even before the neurodegeneration cascade (Haass and
Selkoe, 2007). In parallel, the early accumulation of Aβ oligomers
in cerebral microvessels causes vascular dysfunction and con-
tributes to the development of Cerebral Amyloid Angiopathy
(CAA), which takes place in 80% of AD cases (Bell and Zlokovic,
2009). Interestingly, microvascular dysfunction has been reported
at the early stages of AD pathogenesis (Zlokovic, 2005), outlining
a central role of cerebrovascular dysfunction in AD development
(Pimentel-Coelho and Rivest, 2012). Indeed, abnormalities at the
Blood-Brain Barrier (BBB) have been reported in AD (Desai et al.,
2007), supporting this hypothesis.
The BBB constitutes a physical barrier separating the periph-
eral circulation from the central nervous system (CNS), and plays
a central and major role in controlling brain homeostasis and
regulating brain microenvironment, by (1) precisely adjusting
nutrient and oxygen delivery based on brain needs, (2) removing
toxic metabolites from the brain into the blood, (3) protecting the
brain from endogenous and exogenous toxic molecules, and (4)
supporting parenchymal tissue viability (Löscher and Potschka,
2005). The BBB adopts a special phenotype characterized by a
high transendothelial electrical resistance (TEER), thus prevent-
ing the free passage of blood-borne molecules and cells from
brain entry (Zlokovic, 2008). Anatomically, the BBB is consti-
tuted by specialized endothelial cells that actively interact with
Extracellular Matrix (ECM) proteins that form the perivascu-
lar space, pericytes, astrocytes, microglia and neurons, forming
the neurovascular unit (NVU), which is the functional unit of
the BBB (Zlokovic, 2011). The NVU has two functionally dis-
tinct sides, the luminal side facing the blood circulation, and the
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abluminal side facing the brain parenchyma (Hermann and ElAli,
2012). To fulfill its role in controlling brain homeostasis and reg-
ulating brain microenvironment, the cells forming the NVU are
complemented by sophisticated active transport systems, such as
ion channels, pumps, receptors, and transporters, among which
are the transmembrane transporters belonging to Adenosine
Triphosphate-Binding Cassette (ABC) transporter family.
The ABC transporter family consists essentially of 48 pro-
teins in humans, which are subdivided into 7 sub-families (ABC1,
MDR/TAP, MRP, ALD, OABP, GCN20, White) (de Lange, 2004;
Leslie et al., 2005). Initially, ABC transporters were discovered
by oncologists to be responsible for chemotherapy resistance
(Biedler and Riehm, 1970). ABC transporters use energy gener-
ated from ATP hydrolysis to transport substrates across cell mem-
branes (ElAli and Hermann, 2011), and have overlapping affinity
for many lipophilic and amphipathic molecules, therefore phys-
iologically considered as cell detoxification systems (de Lange,
2004). ABC transporters, depending on the sub-family, act either
as gatekeepers by protecting organs from toxic compounds, or
as transporters of bioactive molecules produced by cells (Leslie
et al., 2005). Two ABC transporters have been shown to play
important roles in AD pathogenesis; (1) ABC transporter sub-
family B member 1 (ABCB1; i.e., Multi Drug Resistance Protein;
Mdr-1) that acts as an efflux pump of xenobiotic molecules,
and (2) the ABC transporter sub-family A member 1 (ABCA1;
i.e., Cholesterol Efflux Regulatory Protein; CERP) that acts as an
efflux pump for cholesterol and phospholipids from cell mem-
branes to Apolipoprotein E (ApoE) and ApoA-I (Wahrle et al.,
2005; Kuhnke et al., 2007).
Two main mechanisms govern Aβ clearance at the NVU, Aβ
degradation by specialized enzymes, and Aβ transport across the
BBB, from the brain into blood circulation (Nalivaeva et al.,
2012; Sagare et al., 2012). Recently, it has been proposed that
impaired Aβ transport, elimination, and clearance across the
BBB/NVU constitute key steps in AD pathogenesis, as it causes
an excessive accumulation of Aβ in brain parenchyma, induc-
ing neuronal dysfunction and favoring Aβ plaques formation
(Zlokovic, 2008). This hypothesis suggests that the dysfunction
of the BBB/NVU causatively contributes to the pathogenesis of
AD (Zlokovic, 2011), which is now under intense investigation.
Several ABC transporters have been reported to be involved in
Aβ processing, transport, and clearance at the NVU (Abuznait
and Kaddoumi, 2012), among which ABCB1, and ABCA1 are the
most studied and characterized. As such, in this minireview, we
would like firstly to summarize the known roles of ABCB1 and
ABCA1 expressed by the different cell types forming the NVU in
Aβ clearance from brain parenchyma andmicrovessels into blood
circulation, secondly to propose possible mechanisms for Aβ
clearance through the NVU based on the existing literature, and
finally to discuss the potential of ABCB1 and ABCA1 modulation
as a new therapeutic strategy in CAA, and AD treatment.
β-AMYOID CLEARANCE BY BRAIN ENDOTHELIAL CELLS
Being the first line of defense, brain endothelial cells express
high level of ABC transporters, especially drug transporters that
extrude toxic molecules from the brain, namely ABCB1. ABCB1
is highly expressed at the luminal side of brain endothelial cells,
and is considered as marker of BBB maturity and functionality
(Hermann and ElAli, 2012). It has been reported that soluble
Aβ is transported across brain endothelial cells and eliminated
from the brain into blood circulation, mainly via the low-
density lipoprotein-related protein-1 (LRP-1) in collaboration
with ABCB1 (Zlokovic, 2008). For instance, it has been shown
that Aβ binds to ABCB1, and that the latter is directly involved in
its active transport (Lam et al., 2001). In parallel, LRP-1 can bind
directly Aβ or via ligands that bind Aβ, such as ApoE (Yamada
et al., 2008). As such, LRP-1/ABCB1 seems to form an efficacious
and complete transport system that coordinates Aβ transport
and elimination from the brain. Interestingly, the pharmacolog-
ical inhibition of ABCB1 decreased Aβ clearance in vitro (Lam
et al., 2001; Kuhnke et al., 2007), outlining the direct involve-
ment of ABCB1 in Aβ clearance. These in vitro observations were
confirmed by in vivo studies where abca1a/b−/− knockout mice
intracerebrally injected with Aβ exhibited reduced clearance of
these peptides compared to control littermates (Cirrito et al.,
2005). In human, experiments on post-mortem tissue samples
of AD patients showed decreased expression levels of ABCB1 in
brain endothelial cells of microvessels that surround Aβ deposits
(Vogelgesang et al., 2002), and almost no expression of ABCB1
in brain endothelial cells was detected in post-mortem tissue
samples obtained from CAA patients (Vogelgesang et al., 2004).
It is noteworthy, that ABCB1 expression in brain endothelial
cells decreases with physiological aging, as shown in long-lived
B-N/F rats, which interestingly caused brain accumulation of
exogenously administered Aβ (Silverberg et al., 2010). In human
brain, ABCB1 expression has been reported to decrease in elderly
subjects (Bartels et al., 2009). This observation is highly impor-
tant, because the decreased expression of ABCB1 impeded NVU’s
capacity in acting as a gatekeeper for the brain, allowing endoge-
nous and exogenous toxins, like Aβ, to accumulate in the brain,
thus inducing neuronal dysfunction. Taken together, these reports
and studies strongly suggest and advocate a central role of ABCB1
expression in brain endothelial cells in AD pathogenesis, by
affecting Aβ transport across the brain endothelium.
In contrast to ABCB1, ABCA1 does not directly bind and
extrude Aβ. In brain endothelial cells, ABCA1 is expressed at the
abluminal side of the endothelium (Panzenboeck et al., 2002).
Experiments conducted in abca1−/− knock-out mice showed that
ABCBA1 controls Aβ degradation fate and its ability to form
aggregates, via an ApoE dependent manner, thus enhancing its
clearance from the brain (Akanuma et al., 2008). Being a regula-
tor of cholesterol efflux, ABCA1 controls protein levels of ApoE
and its lipidation state, which constitutes an important factor in
the capacity of ApoE to efficiently bind Aβ (Tokuda et al., 2000).
As such, highly lipidated ApoE binds more efficiently Aβ and
diminishes its capacity to aggregate by modulating its conforma-
tion (Wahrle et al., 2004; Holtzman et al., 2012). Interestingly,
it was reported that PDAPP/abca1 transgenic mice that overex-
press ABCA1, have reduced Aβ deposits in brain parenchyma
compared to their littermates, and almost complete absence of
vascular Aβ deposits (Wahrle et al., 2008), outlining an efficient
elimination of Aβ across the NVU. This observation is intriguing
giving the fact that ABCA1 does not physically bind and eliminate
Aβ. As such, we propose a mechanism via which the abluminal
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ABCA1, upon its activation, induces efficient ApoE lipidation,
thus facilitating ApoE/Aβ interaction in the perivascular space,
making Aβmore accessible to LRP-1/ABCB1 transport system at
the NVU (Figure 1).
β-AMYLOID CLEARANCE BY PERICYTES
Pericytes are tightly associated to the abluminal side of brain
microvessels and covers approximately 25% of their circumfer-
ence (Hellström et al., 2001). Brain pericytes act as vascular
smooth cells (vSMC) by expressing several receptors of vasoac-
tive molecules, therefore playing a major role in controlling
brain microvascular tone (Armulik et al., 2011). Pericytes play
an important role in regulating endothelial cell proliferation, sur-
vival, and migration (Hellström et al., 2001), and are required
for BBB formation and induction by down-regulating genes asso-
ciated with vascular permeability (Daneman et al., 2010), and
inducing the functional activity of ABCB1 in brain endothelial
cells (Al Ahmad et al., 2011). Moreover, some reports showed
that brain pericytes behave like immune cells under stress by
expressing the macrophage markers ED-2 and CD11b, and have
some basal phagocytosis capacities (Kovac et al., 2011). Besides,
it was reported that a high concentration of Aβ induces pericytes
apoptosis (Verbeek et al., 1997), and differentially regulates per-
icytic genes at lower Aβ concentrations (Rensink et al., 2004).
Interestingly, it has been shown that pericytes express LRP-1, and
this expression has been shown to be modulated by Aβ loading
(Wilhelmus et al., 2007). In parallel, ABCB1 has been reported
to be expressed in pericytes (Berezowski et al., 2004; Bendayan
FIGURE 1 | ABCA1/ABCB1 Transport Systems in the NVU: Proposed
mechanism via which ABCA1/ApoE—LRP-1/ABCB1 systems in the
NVU cooperate in order to efficiently mediate Aβ clearance from brain
parenchyma, and microvessels into blood circulation. ABCA1 in brain
endothelial cells, pericytes, astrocytes, and microglial cells enhances ApoE
lipidation, and with the collaboration of ABCB1 facilitates Aβ trafficking into
the perivascular space, where it can be subsequently eliminated into blood
circulation via LRP-1/ABCB1 in brain endothelial cells.
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et al., 2006). Taken together, these reports would suggest a poten-
tial role of the LRP-1/ABCB1 system in Aβ clearance, a hypothesis
that merits further investigations. Recently, it has been reported
that pericytes express ABCA1, which upon stimulation enhance
ApoE lipidation without affecting the fate of the internalized
Aβ (Saint-Pol et al., 2012). As such, it is very probable that the
stimulation of ABCA1 in pericytes, in parallel to ABCA1 at the
abluminal side of brain endothelial cells, further enhances ApoE
production and lipidation at the perivascular space, diminishing
the capacity of Aβ to aggregate in the perivascular space, and
makes soluble Aβ more accessible to be cleared across the NVU
(Figure 1).
β-AMYLOID CLEARANCE BY ASTROCYTES
Astrocyte endfeet cover up to 90% of brain microvessels, and
play an essential role in inducing BBB features (Davson and
Oldendorf, 1967). The presence of astrocytes is a prerequisite
for BBB integrity by enhancing tight junction proteins expres-
sion and BBB functionality by inducing the expression of ABCB1
at the luminal side of brain endothelial cells (Abbott et al.,
2006). Although the physiological level of ABCB1 expression
in astrocytes is low and the exact role of this basal expres-
sion is totally unknown, it is well reported that under patho-
physiological conditions, such as epilepsy, ABCB1 expression
is highly increased and specifically at the endfeet of reactive
astrocytes, thus playing a major role in epileptic drug resis-
tance (Sisodiya et al., 2002). The expression levels of ABCB1
in astrocytes in AD are still to be investigated, but it would be
highly surprising that its expression in astrocytes does not change
in AD.
Nonetheless, it has been shown that astrocytes close to plaques
express LRPs and internalize Aβ in an ApoE dependent manner
(Arélin et al., 2002). The fate of Aβ uptaken by astrocytes is still
elusive, as it has been proposed that the accumulation of Aβ can
induce astrocytes dysfunction and contribute in the pathogenesis
of AD (Nagele et al., 2003), or can be degraded (Wyss-Coray et al.,
2003). Giving the fact that most intra-astrocytic Aβ are of neu-
ronal origin (Nagele et al., 2003), and internalized mainly from
cored plaques (Arélin et al., 2002), it is very probable, although
speculative, that portions of internalized Aβ are trafficked toward
endfeet facing the abluminal side of brain endothelial cells, where
they can be eliminated in the perivascular space and be cleared
into blood circulation by the brain endothelial cells transport
system, LRP-1/ABCB1.
In addition, astrocytes express high level of ABCA1, which
as discussed above, plays a crucial role in the lipidation of
astrocyte-produced ApoE (Wahrle et al., 2004), thus facilitating
Aβ clearance by reducing Aβ aggregation (Holtzman et al., 2012).
As such, astrocytes contribute in Aβ clearance by making Aβ
more diffusible and more accessible to be cleared across the NVU
(Figure 1).
β-AMYLOID CLEARANCE BY MICROGLIA
Microglial cells are the resident macrophages of the brain, consti-
tuting the first line of immune defense (Bellavance and Rivest,
2012). They act as continuous scavengers at the brain for Aβ
plaques, debris, apoptotic neurons (Naert and Rivest, 2011),
surveying closely the smallest changes in the brain, and exhibit-
ing significant phagocytosis capacities (Naert and Rivest, 2011).
Although microglial cells are closely associated to Aβ plaques
in vivo, they do not appear to be efficient in clearing Aβ deposits
(Bolmont et al., 2008). Interestingly, microglial cells are still able
to internalize both fibrillar Aβ and soluble Aβ which would sug-
gest that internalization of Aβ is not always accompanied by their
degradation (Pan et al., 2011), outlining a different fate for these
internalized Aβ peptides. Similar to astrocytes, ABCB1 expression
in microglia is low under physiological conditions (Wolf et al.,
2012), but has been shown to be increased in epilepsy (Löscher
and Potschka, 2005). The expression levels of ABCB1 in microglia
cells in AD are totally unknown, but as microglial cells have the
ability to internalize Aβ, it would be probable that ABCB1 in
microglial cells plays a role in Aβ transport. Similar to astrocytes,
microglial cells express high levels of ABCA1 and contribute to
ApoE production and lipidation in the brain, therefore contribute
to Aβ clearance (Hirsch-Reinshagen et al., 2004) (Figure 1).
PHARMACOLOGICALMODULATION OF ABCB1 AND ABCA1
AT THE LEVEL OF NVU AS A THERAPEUTIC APPROACH
ABCB1 plays a key role in Aβ transport and clearance at dif-
ferent levels of the NVU. This role could be highly relevant in
developing new strategies to treat AD. Indeed, ABCB1 is induced
following activation of the Orphan Nuclear Receptor (ONR),
Pregnane X Receptor (PXR) in brain microvessels of humans
(Bauer et al., 2006). A clinical study conducted in AD patients
with mild cognitive deficits concluded that both doxycycline and
rifampicin efficaciously reduce the cognitive decline in treated
patients (Loeb et al., 2004), possibly and partly via a mechanism
involving ABCB1, as both molecules have been reported to induce
ABCB1 expression (Wolf et al., 2012). In parallel, it has been
shown, in a mouse model of AD that inducing the expression
of ABCB1 by stimulating PXR, highly decreased Aβ brain accu-
mulation (Hartz et al., 2010). More recently, it has been reported
that the stimulation of Retinoid X Receptor (RXR) using the ago-
nist bexarotene in a mouse model of AD enhanced soluble Aβ
clearance in an ApoE dependent manner (Cramer et al., 2012). It
is noteworthy that RXR binds as a heterodimer with PXR to the
PXR-responsive element regulating abcb1 gene expression (Geick
et al., 2001). Finally, ABCB1 constitutes a main target gene of
nuclear receptors, as even the stimulation of Liver X Receptor
(LXR) with agonists has been reported to potently induce ABCB1
expression in brain microvessels (ElAli and Hermann, 2012). The
induction of ABCB1 by nuclear receptors’ stimulation could be a
highly attractive strategy, because it allows in parallel to induce
the expression of ABCA1 and ApoE, and the lipidation of the
latter (Koldamova et al., 2003; Donkin et al., 2010).
CONCLUSION
The expression of ABCB1 and ABCA1 in all cells forming the
NVU is of high importance, because it would constitute an ele-
gant mechanism via which the ABCA1/ApoE and LRP-1/ABCB1
systems work in concert and cooperate to facilitate Aβ trans-
port from plaques towards brain microvessels, and its subse-
quent clearance into blood circulation. Most of the parenchymal
deposits are relatively far from functional brain microvessels,
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as such the mechanism proposed here suggests Aβ traffick-
ing towards the perivascular space and abluminal side of brain
endothelial cells, in order to be cleared into blood circulation. As
such, we believe that the up-regulation and function of ABCB1
and ABCA1, not only in brain endothelia, but in all cells forming
the NVU (Figure 1), may enhance Aβ clearance from the brain
more efficiently, consequently reducing Aβ deposition in both
parenchyma and perivascular space. This mechanism provides a
novel approach to be considered in parallel with other strategies
in treating CAA and AD.
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